argenx (ARGX) vs Cogent Biosciences (COGT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed argenx (ARGX) over the past year, gaining 93.1% versus a gain of 2.5%. Over five years, COGT leads with a +225.5% price change compared with +178.7% for ARGX. argenx is the larger company by market cap ($50.93 billion vs $5.22 billion), about 9.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | COGT |
|---|---|---|
| Share price | $809.94 | $30.11 |
| Market cap | $50.93B | $5.22B |
| 1-day change | -1.06% | +0.10% |
| YTD return | -2.65% | -15.32% |
| 1-year return | +2.46% | +93.07% |
| 5-year return | +178.69% | +225.54% |
| P/E ratio (TTM) | 30.87 | — |
| Forward P/E | 23.33 | — |
| EPS (TTM) | $26.24 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.29B | $-328.94M |
| 52-week high | $1,072.75 | $43.73 |
| 52-week low | $661.85 | $13.78 |
| Distance from 52-week high | -24.50% | -31.15% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.70% | +85.39% |
| Average volume | 317.26K | 1.90M |
| Shares outstanding | 62.89M | 173.52M |
| Employees | 1,863 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 9.7 times larger than Cogent Biosciences by market value ($50.93B vs $5.22B).
- COGT has outperformed ARGX by 90.6 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ARGX vs COGT FAQ
Which is bigger, argenx or Cogent Biosciences?
argenx (ARGX) is larger, with a market capitalization of $50.93B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, ARGX or COGT?
COGT returned +93.07% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Cogent Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Pharmaceutical Preparations for Cogent Biosciences.